Preclinical data has demonstrated that the oral small molecule OLX-07010 inhibits tau aggregation in a model for inherited tauopathies such as progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD). Earlier this year, the company Oligomerix announced the first-in-human dosing of OLX-07010 in a Phase Ia clinical trial. “While there has been significant progress in the […]
